FIGS, Inc. Q3 2025 10-Q Summary
Business Context and Reporting Period
Company: FIGS, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: FIGS is a direct-to-consumer healthcare apparel and lifestyle brand, primarily selling scrubwear and non-scrubwear through digital platforms and a growing network of physical "Community Hub" retail stores. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Revenues | $151.7 million | $140.2 million | $429.2 million | $403.7 million |
| Gross Profit | $106.1 million | $94.0 million | $292.8 million | $273.4 million |
| Gross Margin | 69.9% | 67.1% | 68.2% | 67.7% |
| Operating Income | $9.6 million | $(8.6) million | $19.3 million | $(6.6) million |
| Net Income | $8.7 million | $(1.7) million | $15.7 million | $0.8 million |
| Diluted EPS | $0.05 | $(0.01) | $0.09 | $0.00 |
| Adjusted EBITDA | $18.9 million | $4.8 million | $47.8 million | $30.7 million |
| Free Cash Flow (9M) | $(5.1) million | $37.1 million | — | — |
| Cash & Equivalents (End of Period) | $46.5 million | — | — | — |
Note: Free Cash Flow for the nine months ended Sept 30, 2025, was negative $5.1 million compared to positive $37.1 million in the prior year period.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 8.2% in Q3 and 6.3% YTD, driven by higher order volumes and an increase in Average Order Value (AOV) to $114 in Q3 (up from $108 in Q3 2024).
- Profitability Turnaround: The company returned to profitability in Q3 2025 ($8.7M net income) compared to a net loss of $1.7M in Q3 2024. Operating expenses decreased 6.1% in Q3, primarily due to reduced marketing spend (lapping 2024 Olympics campaign) and lower fulfillment costs.
- Cash Flow Deterioration: Operating cash flow for the nine months ended Sept 30, 2025, dropped significantly to $0.2 million from $50.7 million in the prior year. This was driven by a $31.1 million increase in inventory purchases and timing of payments for accrued expenses and accounts payable.
- Inventory Build: Inventory levels rose to $151.2 million (up from $115.8 million at year-end 2024) as the company stocked up to mitigate supply chain volatility.
Guidance, Outlook, and Risks
- Tariff Impact: Management estimates current U.S. tariffs (10% baseline plus country-specific rates for Vietnam and Jordan) will negatively impact gross margin by approximately 110 basis points in 2025 and 440 basis points in 2026. Mitigation strategies include sourcing adjustments and supplier renegotiations.
- Share Repurchases: The Board authorized a total of $100 million for share repurchases (increased by $50M in Feb 2025). As of Sept 30, 2025, approximately $52.0 million remains available. No repurchases were made in Q3 2025.
- Debt Facility: On November 3, 2025, the company amended its credit agreement to extend the maturity date to November 3, 2030, and reduce the annual commitment fee to 0.15%. No borrowings were outstanding as of Sept 30, 2025.
- Key Risks:
- Supply Chain & Trade Policy: Reliance on Vietnam and Jordan for production exposes the company to tariff volatility and geopolitical risks (e.g., Middle East conflict).
- Customer Concentration: Success depends on retaining healthcare professionals; workforce stress or decline could impact demand.
- Legal Proceedings: A securities class action was dismissed with prejudice in Jan 2025, but plaintiffs have appealed. Derivative suits remain pending.
Investor Verification Checklist
- Inventory Valuation: Verify the adequacy of inventory reserves given the $35.5 million increase in inventory and potential obsolescence risks from slower-than-expected sales.
- Tariff Mitigation: Assess the effectiveness of sourcing diversification strategies to offset the projected 440 bps gross margin hit in 2026.
- Cash Burn Rate: Monitor the sustainability of the negative free cash flow trend ($5.1M outflow YTD) against the $46.5M cash balance and $95.1M available credit facility.
- Legal Exposure: Track the status of the appeal regarding the dismissed securities class action and ongoing derivative suits.
- Marketing Efficiency: Evaluate whether the reduction in marketing spend (down 17.7% in Q3) impacts long-term customer acquisition and retention rates.